Published in Blood on July 08, 2014
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia (2014) 1.28
An update of current treatments for adult acute myeloid leukemia. Blood (2015) 1.23
Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. Transl Oncol (2015) 1.12
Emerging therapeutic drugs for AML. Blood (2015) 1.04
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol (2015) 1.00
Novel drugs for older patients with acute myeloid leukemia. Leukemia (2014) 0.99
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol (2015) 0.96
New drugs in acute myeloid leukemia. Ann Oncol (2016) 0.88
Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends Pharmacol Sci (2015) 0.87
Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol (2015) 0.86
Update on rational targeted therapy in AML. Blood Rev (2016) 0.85
The role of Plk3 in oncogenesis. Oncogene (2015) 0.83
Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer. Am J Cancer Res (2015) 0.82
Targeting polo-like kinase 1 in acute myeloid leukemia. Ther Adv Hematol (2015) 0.82
Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer (2017) 0.81
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Mol Cancer Ther (2016) 0.80
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. Cancer Sci (2015) 0.79
Acute myeloid leukemia in the older adults. Leuk Res Rep (2016) 0.79
Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Invest New Drugs (2015) 0.78
Volasertib for AML: clinical use and patient consideration. Onco Targets Ther (2015) 0.77
Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma. Clin Transl Med (2016) 0.76
Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells. Cancer Sci (2016) 0.76
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia. PLoS One (2016) 0.76
Acute Myeloid Leukemia in the Elderly Patient: New Strategies. Rare Cancers Ther (2015) 0.75
Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. Oncotarget (2016) 0.75
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo. Oncotarget (2017) 0.75
Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies. Front Oncol (2015) 0.75
DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders. Front Oncol (2016) 0.75
Key drivers of biomedical innovation in cancer drug discovery. EMBO Mol Med (2014) 0.75
Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Oncotarget (2016) 0.75
Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Am J Cancer Res (2016) 0.75
Emerging therapies for acute myeloid leukemia. J Hematol Oncol (2017) 0.75
Future prospects of therapeutic clinical trials in acute myeloid leukemia. Future Oncol (2016) 0.75
Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials. J Cancer (2017) 0.75
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer (2017) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
Age and acute myeloid leukemia. Blood (2006) 6.46
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol (2007) 5.17
Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer (2006) 4.99
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood (2008) 4.66
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov (2010) 3.84
Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer (2010) 3.74
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood (2011) 3.32
Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol (2006) 2.63
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol (2009) 2.46
Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J Clin Oncol (2012) 2.23
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol (2009) 1.98
BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res (2009) 1.90
Targeting Polo-like kinase in cancer therapy. Clin Cancer Res (2010) 1.76
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol (2010) 1.70
A review of methods for futility stopping based on conditional power. Stat Med (2005) 1.69
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist (2009) 1.59
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer (2011) 1.51
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood (2013) 1.36
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood (2009) 1.31
Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res (2005) 1.28
An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.17
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther (2012) 1.10
AML in older patients: are we making progress? Best Pract Res Clin Haematol (2009) 1.08
TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther (2011) 1.02
Two-stage adaptive strategy for superiority and non-inferiority hypotheses in active controlled clinical trials. Stat Med (2004) 0.90
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol (2013) 0.87